コカイン使用障害 - 市場考察、疫学、市場予測（2034年）

主なハイライト

• コカイン使用障害とは、医学的、心理学的、行動学的影響があるにもかかわらず、コカインを強迫的に使用することです。コカイン使用障害は深刻な公衆衛生上の問題であり、世界中で数百万人が罹患しています。この壊滅的な障害は個人と社会の両方に影響を及ぼします。
• 短期間のコカイン使用は、精神的覚醒、極度の幸福感、エネルギー、視覚、聴覚、触覚に対する過敏性、過敏性の徴候を示します。コカインのその他の健康への影響は、瞳孔散大、血管収縮、吐き気、落ち着きのなさ、体温上昇です。
• DSM-5によれば、2つか3つの症状は軽度のCUD、4つか5つの症状は中等度のCUD、6つ以上の症状は重度のCUDを示します。
• 主要な医師によると、CUDに対しては、偶発性管理や薬剤使用障害に対する認知行動療法（CBT-SUD）のような心理社会的治療がゴールドスタンダードであることが証明されています。
• これまでのところ、米国食品医薬品局（FDA）の承認基準を満たした薬剤療法や、有効性が証明された薬剤療法はありません。現在のCUD薬理学的治療には、抗うつ薬（citalopram）、選択的セロトニン再取り込み阻害薬（SSRI）、精神刺激薬（methadone、diacetylmorphine）、ドパミン作動薬（amantadine、modafinil）、ドパミン遮断薬（CLOZARIL、ketamine）などの適応外治療があります。
• CUDに対する標準的な治療法がないことが、臨床開発の妨げとなっています。指針となるプロトタイプがなければ、新治療法の開発は困難であることが証明されています。さらに、CUDの病態生理学的特徴に関する現在の理解は、有益な薬理学的治療法を開発するにはまだ不十分です。
• 米国のNational Institutes of HealthのNational Institute on Drug Abuse（NIDA）は、CUD治療に向けた薬剤開発パイプラインを支援しています。
• パイプラインは乏しいですが、DelveInsightは、Mavoglurant、EMB-001などが予測期間（2024年～2034年）に主要7市場で上市し、CUDの断薬誘導に用いる標識療法として成功すると予測しています。
• 2023年、コカイン使用障害と診断された患者数は米国がもっとも多く、次いで英国でした。
• 主要7市場では、男性のコカイン使用障害患者数が女性より多いことが報告されています。
• 米国では、2023年にCUDと診断された患者数がもっとも多かったのは26歳の集団でした。

市場

STALICLA、Embera NeuroTherapeuticsなど、少数の主要企業がコカイン使用障害の治療情勢をリードしています。国別と治療法別の市場規模の詳細は以下の通りです。

• 主要7市場のコカイン使用障害の総市場規模のうち、米国が2023年に55%を超えるもっとも高い市場シェアを占め、ドイツ、英国がこれに続きました。
• 欧州4ヶ国・英国の中では、ドイツが2023年の市場規模の25%近くを占めています。
• 米国は2023年に約3,000万米ドルを占めました。
• 現在、コカイン使用障害の治療には標準治療（SOC）のみが唯一の選択肢として使用されています。

コカイン使用障害（CUD）市場の見通し

現在、コカイン依存症やCUDの治療薬として承認されているものはありませんが、コカイン中毒に関与するプロセスの解明が近年進み、研究者らは有望な新薬候補をいくつか同定しています。グループカウンセリング、個別薬剤カウンセリング、認知行動療法（CBT）、コンティンジェンシーマネジメントなど、複数の心理学的治療は効果的ですが、多くの患者はまだこれらの治療に反応せず、高い脱落率と関連しています。数十年にわたる活動にもかかわらず、CUDは薬剤療法的介入にあまり反応していません。とはいえ、神経生物学的な理解は、長時間作用型アンフェタミンやmodafinilを含むドパミン作動薬、topiramateを含むアミノ酪酸（GABA）/グルタミン酸作動薬のような潜在的な薬剤の発見につながっています。topiramateと混合アンフェタミン塩のようないくつかの併用投薬も有望と見られます。

一言で言えば、コカイン使用障害の治療法として検討されているものはそれほど多くありません。予測期間（2024年～2034年）に市場に参入する上記の有望な候補についてコメントするのは時期尚早です。最終的には、この薬剤は今後数年間で、コカイン使用障害の情勢に大きな変化をもたらすと見られます。この治療領域は、世界中での医療費の向上により、今後数年間で大きくプラスに転じると予測されます。

当レポートでは、コカイン使用障害（CUD）の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 重要考察

第2章 レポートのイントロダクション

第3章 CUD市場の概要

• 主要7市場のCUDの市場シェアの分布（2023年）
• 主要7市場のCUDの市場シェアの分布（2034年）

第4章 調査手法

第5章 CUDのエグゼクティブサマリー

第6章 重要な出来事

第7章 CUDの疾患背景と概要

• CUDのイントロダクション
• 兆候と症状
• コカイン使用障害のDSM 5基準：CUDの兆候と症状
• CUDの分類
• 病因
• 危険因子
• 病態生理学
  • ドパミンの脳内報酬メカニズム
  • 腹側淡蒼球におけるセロトニン濃度の乱れ
  • コリン作動性経路
• コカイン使用の合併症
• 診断
  • 主な診断要因
  • その他の診断要因
  • 診断検査
  • CUDのDSM-5診断基準
  • 物質使用障害の診断と分類のDSM-5診断基準

第8章 管理と治療

• 非薬剤治療
• 薬剤治療
• 治療ガイドライン

第9章 疫学と患者人口

• 主な調査結果
• 前提条件と根拠：主要7市場
• 主要7市場のCUDの総診断患者数
• 主要7市場のCUDの総治療患者数
• 米国
• 欧州4ヶ国・英国
• 日本

第10章 ペイシェントジャーニー

第11章 新治療法

第12章 市場の分析

• 主な調査結果
• 市場見通し
• コンジョイント分析
• 主な市場予測の前提条件
  • コストの想定とリベート
  • 価格動向
  • アナログの評価
  • 発売年と治療の普及
• 主要7市場のCUDの総市場規模
• 米国の市場規模
  • 米国のCUDの総市場規模
  • 米国のCUDの市場規模：治療法別
• 欧州4ヶ国・英国の市場規模
  • 欧州4ヶ国・英国のCUDの総市場規模
  • 欧州4ヶ国・英国のCUDの市場規模：治療法別
• 日本の市場規模
  • 日本のCUDの総市場規模
  • 日本のCUDの市場規模：治療法別

第13章 KOLの見解

第14章 SWOT分析

第15章 アンメットニーズ

第16章 付録

第17章 DelveInsightのサービス内容

第18章 免責事項

List of Tables

• Table 1: Summary of CUD Market and Epidemiology (2023-2034)
• Table 2: Key Events for CUD
• Table 3: Complications of Cocaine Use
• Table 4: Diagnostic Tests for Cocaine Use Disorder
• Table 5: Other Tests to Consider for Cocaine Use Disorder
• Table 6: DSM-5 Diagnostic Criteria for Diagnosing and Classifying Substance Use Disorders
• Table 7: Treatment Algorithm of CUD
• Table 8: Summary of the Evidence on Pharmacotherapies for Cocaine Use Disorder, Stratified by Drug Class
• Table 9: Total Diagnosed Prevalent Cases of CUD in the 7MM (2020-2034)
• Table 10: Total Treated Cases of CUD in the 7MM (2020-2034)
• Table 11: Total Diagnosed Prevalent Cases of CUD in the US (2020-2034)
• Table 12: Gender-specific Cases of CUD in the US (2020-2034)
• Table 13: Age-specific Cases of CUD in the US (2020-2034)
• Table 14: Severity-specific Cases of CUD in the US (2020-2034)
• Table 15: Total Treated cases of CUD in the US (2020-2034)
• Table 16: Total Prevalent Cases of Osteogenesis Imperfecta in EU4 and the UK (2020-2034)
• Table 17: Gender-specific cases of CUD in EU4 and the UK (2020-2034)
• Table 18: Age-specific Cases of CUD in EU4 and the UK (2020-2034)
• Table 19: Severity-specific Cases of CUD in EU4 and the UK (2020-2034)
• Table 20: Total Treated cases of CUD in EU4 and the UK (2020-2034)
• Table 21: Total Diagnosed Prevalent Cases of CUD in Japan (2020-2034)
• Table 22: Gender-specific Cases of CUD in Japan (2020-2034)
• Table 23: Age-specific Cases of CUD in Japan (2020-2034)
• Table 24: Severity-specific Cases of CUD in Japan (2020-2034)
• Table 25: Total Treated cases of CUD in Japan (2020-2034)
• Table 26: Comparison of Emerging Drugs Under Development
• Table 27: STP7 (mavoglurant) Clinical Trial Description, 2024
• Table 28: EMB-001: Clinical Trial Description, 2024
• Table 29: Key Market Forecast Assumption of CUD in the United States
• Table 30: Key Market Forecast Assumption of CUD in EU4 and the UK
• Table 31: Key Market Forecast Assumption of CUD in Japan
• Table 32: Total Market Size of CUD in the 7MM, USD million (2020-2034)
• Table 33: Total Market Size of CUD in the US, USD million (2020-2034)
• Table 34: Market Size of CUD by Therapies in the US (2020-2034)
• Table 35: Total Market Size of CUD in EU4 and the UK, USD million (2020-2034)
• Table 36: Market Size of CUD by Therapies in EU4 and the UK, USD million (2020-2034)
• Table 37: Total Market Size of CUD in Japan, USD million (2020-2034)
• Table 38: Market Size of CUD by Therapies in Japan, USD million (2020-2034)

List of Figures

• Figure 1: Symptoms of CUDs
• Figure 2: Classification of CUD Based on Severity
• Figure 3: Etiology of CUD
• Figure 4: Risk Factors of CUD
• Figure 5: Treatment Etiology of Cocaine Drug Abuse
• Figure 6: Disruption of Serotonin Contributing to the Cocaine Effect
• Figure 7: Role of ACh in Drug Dependence, With a Primary Focus on Cocaine and the Muscarinic ACh System
• Figure 8: Diagnostic Factors of CUD
• Figure 9: Treatment Options for CUD
• Figure 10: Total 12-month Diagnosed Prevalent Cases of CUD in the 7MM (2020-2034)
• Figure 11: Total Treated Cases of CUD in the 7MM (2020-2034)
• Figure 12: Total 12-month Diagnosed Prevalent Cases of CUD in the US (2020-2034)
• Figure 13: Gender-specific Cases of CUD in the US (2020-2034)
• Figure 14: Age-specific Cases of CUD in the US (2020-2034)
• Figure 15: Severity-specific Cases of CUD in the US (2020-2034)
• Figure 16: Total Treated cases of CUD in the US (2020-2034)
• Figure 17: Total 12-month Diagnosed Prevalent Cases of CUD in EU4 and the UK (2020-2034)
• Figure 18: Gender-specific Cases of CUD in EU4 and the UK (2020-2034)
• Figure 19: Age-specific Cases of CUD in EU4 and the UK (2020-2034)
• Figure 20: Severity-specific Cases of CUD in EU4 and the UK (2020-2034)
• Figure 21: Total Treated cases of CUD in EU4 and the UK (2020-2034)
• Figure 22: Total 12-month Diagnosed Prevalent Cases of CUD in Japan (2020-2034)
• Figure 23: Gender-specific Cases of CUD in Japan (2020-2034)
• Figure 24: Age-specific Cases of CUD in Japan (2020-2034)
• Figure 25: Severity-specific Cases of CUD in Japan (2020-2034)
• Figure 26: Total Treated cases of CUD in Japan (2020-2034)
• Figure 27: Total Market Size of CUD in the 7MM (2020-2034)
• Figure 28: Total Market Size of CUD in the US (2020-2034)
• Figure 29: Market Size of CUD by Therapies in the US (2020-2034)
• Figure 30: Total Market Size of CUD in EU4 and the UK (2020-2034)
• Figure 31: Market Size of CUD by Therapies in EU4 and the UK (2020-2034)
• Figure 32: Total Market Size of CUD in Japan (2020-2034)
• Figure 33: Market Size of CUD by Therapies in Japan (2020-2034)
• Figure 34: Unmet Needs

Key Highlights:

• Cocaine Use Disorder is the compulsive use of cocaine despite its medical, psychological, and behavioral consequences. It is a severe public health problem, affecting millions of people globally. The devastating disorder impacts both individuals and society.
• Short-term cocaine use shows signs of mental alertness, extreme happiness, and energy, hypersensitivity to sight, sound, touch, and irritability. Other health effects of cocaine are dilated pupils, constricted blood vessels, nausea, restlessness, and raised body temperature.
• As per the DSM-5, two or three symptoms indicate mild CUD, four or five symptoms indicate moderate CUD and six or more symptoms indicate severe CUD.
• According to leading physicians, psychosocial treatments like contingency management and cognitive-behavioral therapy for substance use disorders (CBT-SUD) have proved gold standards for CUD.
• So far, no medication has met the US Food and Drug Administration's (FDA) criteria for approval or has proven to be effective; current CUD pharmacological treatment includes the use of off-label therapies with antidepressants (citalopram), selective serotonin reuptake inhibitor (SSRI), psychostimulants (methadone and diacetylmorphine), dopamine agonists (amantadine and modafinil), dopamine blockers (CLOZARIL and ketamines), and others.
• The absence of a standard treatment for CUD has hampered clinical development. Without a guiding prototype, developing new treatments has proven challenging. Furthermore, the current understanding of the pathophysiologic characteristics of CUD remains insufficient for developing beneficial pharmacological therapies.
• The National Institute on Drug Abuse of the National Institutes of Health (NIDA) supports the medication development pipeline for treating CUD.
• Though the pipeline is scarce, DelveInsight forecasts that Mavoglurant, EMB-001 and others would prove to be successful labeled therapies for inducing abstinence in CUD with their launch in the 7MM in the forecast period (2024-2034).
• In 2023, the United States accounted for the highest diagnosed prevalent cases of Cocaine Use Disorder followed by the United Kingdom.
• In the 7MM, males reported more cases than females for Cocaine Use Disorder.
• In the United States, individuals of the =26 age group accounted for the highest number of diagnosed CUD cases in 2023.

Report Summary

• The report offers extensive knowledge regarding the epidemiology segments and predictions, presenting a deep understanding of the potential future growth in diagnosis rates, disease progression, and treatment guidelines. It provides comprehensive insights into these aspects, enabling a thorough assessment of the subject matter.
• Additionally, an all-inclusive account of the current management techniques and emerging therapies and the elaborative profiles of late-stage (Phase II and Phase I) and prominent therapies that would impact the current treatment landscape and result in an overall market shift has been provided in the report.
• The report also encompasses a comprehensive analysis of the Cocaine Use Disorder market, providing an in-depth examination of its historical and projected market size (2020-2034). It also includes the market share of therapies, detailed assumptions, and the underlying rationale for our methodology. The report also includes drug outreach coverage in the 7MM region.
• The report includes qualitative insights that provide an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, including experts from various hospitals and prominent universities, patient journey, and treatment preferences that help shape and drive the 7MM cocaine use disorder market.

Market

A few key players are leading the treatment landscape of Cocaine Use Disorder, such as STALICLA, Embera NeuroTherapeutics, and others. The details of the country-wise and therapy-wise market size have been provided below.

• In the total market size of Cocaine Use Disorder in the 7MM, the United States accounted for the highest market share, i.e. more than 55% in 2023, followed by Germany and the United Kingdom.
• Among EU4 and the UK, Germany accounted for almost 25% of the market size in 2023.
• The United States accounted for approximately USD 30 million in 2023.
• Currently, only Standard of Care (SOC) is being used as the only option of therapy for the treatment of Cocaine Use Disorder.

Cocaine Use Disorder (CUD) Drug Chapters

The section dedicated to drugs in the Cocaine Use Disorder report provides an in-depth evaluation of late-stage pipeline drugs (Phase II) related to Cocaine Use Disorder. The drug chapters section provides valuable information on various aspects related to clinical trials of Cocaine Use Disorder, such as the pharmacological mechanisms of the drugs involved, designations, approval status, patent information, and a comprehensive analysis of the pros and cons associated with each drug. Furthermore, it presents the most recent news updates and press releases on drugs targeting Cocaine Use Disorder.

Emerging Therapies

Mavoglurant (STP7/AFQ056): STALICLA

STP7 (mavoglurant) is a selective nonallosteric mGluR5 antagonist. mGluR5 has been tied to mood disorders, addiction, and rare and common forms of autism. The product is believed to block a certain protein in the brain, which research has shown is related to people's craving to use drugs like cocaine. A clinical Phase II study showed mavoglurant-induced abstinence in CUD patients through inhibition of mGluR5, with no evidence of withdrawal liability. The company plans to advance mavoglurant into Phase III development to treat CUD, which will be covered by the US National Institute on Drug Abuse (NIDA). Also, the company will use its precision neurobiology Drug Development Platform (DEPI) to detect subgroups of high-responder patients with rare and common neurodevelopmental disorders where mavoglurant can be an effective treatment, as guided by earlier clinical studies.

EMB-001: Embera NeuroTherapeutics

EMB-001, a patent product, comprises two FDA-approved medications, the cortisol synthesis inhibitor metyrapone (MET) and the benzodiazepine receptor agonist oxazepam, that act as a potential pharmacological treatment for CUD. MET is an 11 B-hydroxylase inhibitor that blocks cortisol synthesis in the brain and adrenal cortex. At the same time, OX is a GABAA-positive allosteric modulator that increases the sensitivity to GABA, the main inhibitory neurotransmitter in the brain. It may also decrease cortisol synthesis in the brain. Through multiple pathways, this combination uniquely targets reducing the cravings and loss of control that drive relapse in addiction, thereby possibly maximizing potential efficacy. EMB-001 acts by mechanisms distinct from those of existing addiction treatments. It is hypothesized to reduce the increased activity in the stress response system induced by drugs, cues, and stressors that contribute to relapse in addiction. The drug has completed the Phase I trial and is currently being investigated under Phase II clinical trial evaluation to treat CUD.

Cocaine Use Disorder (CUD) Market Outlook

Currently, no medications are approved for cocaine dependence or CUD; however, recent advances in understanding the processes involved in cocaine addiction have allowed researchers to identify several promising new candidate medications. Several psychological treatments, including group counseling, individual drug counseling, cognitive behavioral therapy (CBT), and contingency management, are effective; however, many patients still do not respond to these treatments and are associated with high dropout rates. Despite decades of efforts, CUD has not responded well to pharmacotherapeutic interventions. Nevertheless, a significant understanding of neurobiology has led to the discovery of potential medications like dopamine agonists, including long-acting amphetamine, modafinil, and ?-aminobutyric acid (GABA)/glutamatergic medications, including topiramate. A few combination medications, such as topiramate and mixed amphetamine salts, also appear promising.

In a nutshell, not many potential therapies are being investigated to manage Cocaine Use Disorder. Even though it is too soon to comment on the above-mentioned promising candidate to enter the market during the forecast period (2024-2034). Eventually, this drug will create a significant difference in the landscape of cocaine use disorder in the coming years. The treatment space is expected to experience a significant positive shift in the coming years owing to the improvement in healthcare spending worldwide.

Cocaine Use Disorder (CUD) Disease Understanding and Treatment

Cocaine Use Disorder (CUD) Overview

Cocaine use disorder (CUD) is a pattern of cocaine use leading to clinically significant impairment or distress. Cocaine is a powerfully addictive stimulant made from coca plant leaves native to South America. Its use is associated with cardiovascular and neurologic effects, and chronic repeated exposure leads to tolerance, adverse psychological and behavioral effects, and complications, including infections, stroke, and seizure. According to the DSM-5, CUD is classified as mild, moderate, or severe based on the number of symptoms within 12 months. A minimum of two to three DSM-5 criteria is required for a mild diagnosis, between four and five for a moderate diagnosis, and between six and seven for a severe diagnosis.

Cocaine Use Disorder (CUD) Diagnosis

The diagnosis of cocaine use disorder (CUD) involves a combination of physical examination, clinical evaluation, and laboratory testing. Physical examination may reveal external markers of chronic cocaine use, such as cracked lip and thumb caused by heat-related injuries, salmon-colored marks or infected areas from skin sloughing due to subcutaneous injection, and nasal septum perforation from snorting. Common clinical findings include tachycardia, hypertension, diaphoresis, mydriasis, tremulousness, extreme agitation, and mood lability, which may progress to suicidal depression. Urine toxicology screening plays a crucial role when the cause of hyperadrenergic symptoms is unclear; the detection of benzoylecgonine, a long-lasting cocaine metabolite, confirms cocaine use and may be followed by gas chromatography/mass spectrometry for validation. The presence of levamisole, a common cocaine adulterant, can further aid in detection. For patients presenting with chest pain, evaluation begins with ECG and cardiac enzyme analysis, as cocaine use can precipitate acute myocardial infarction, particularly in chronic users with underlying cardiac conditions. Brain imaging and electroencephalograms are warranted for individuals exhibiting seizures, recurrent episodes, or focal neurological symptoms, which may indicate cerebrovascular complications. Comprehensive assessment and targeted testing for associated complications are essential for accurate diagnosis and effective management of CUD.

Cocaine Use Disorder (CUD) Treatment

The treatment of cocaine use disorder (CUD) involves both nonpharmacological and pharmacological approaches. Psychosocial and behavioral interventions are currently the gold standard for managing CUD. Intensive outpatient therapy (IOT), cognitive-behavioral therapy for substance use disorders (CBT-SUD), and contingency management (CM) have proven effective in promoting abstinence and relapse prevention. CM, which uses motivational incentives like vouchers, and CBT-SUD, which focuses on functional analysis and skills training, remain key strategies. However, no pharmacotherapy has been approved for CUD, though promising candidates include dopamine agonists (e.g., modafinil), GABA/glutamate modulators (e.g., topiramate), and novel agents like ketamine, which influences NMDA receptor signaling. Emerging options such as galantamine, a cholinergic agent, are also being explored for their potential role in addressing disruptions in neurotransmitter systems associated with cocaine use. Integrating behavioral and pharmacological approaches remains the most effective strategy for managing CUD.

Cocaine Use Disorder (CUD) Epidemiology

The Cocaine Use Disorder epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total diagnosed prevalent cases, Gender-specific cases, Age-specific cases, Severity-specific cases, and Total treated cases of Cocaine Use Disorder in the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034.

• Among the 7MM, the United States accounted for the highest number of cases of cocaine use disorder in 2023, with nearly 1,160,000 cases. These cases are anticipated to increase by 2034.
• In the United States, individuals of =26 year age group account for the highest number of cases of cocaine use disorder in 2023.
• In the 7MM, the prevalence of males is more than females in Cocaine Use Disorder.
• Among EU4 and the UK, the United Kingdom accounted for the highest number of diagnosed prevalent cases in 2023, while Italy accounted for the least.

KOL Views

To stay abreast of the latest trends in the market, we conduct primary research by seeking the opinions of Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) who work in the relevant field. This helps us fill any gaps in data and validate our secondary research.

We have reached out to industry experts to gather insights on various aspects of Cocaine Use Disorder, including the evolving treatment landscape, patients' reliance on conventional therapies, their acceptance of therapy switching, drug uptake, and challenges related to accessibility. The experts we contacted included medical/scientific writers, professors, and researchers from prestigious universities in the US, Europe, the UK, and Japan.

Our team of analysts at Delveinsight connected with more than 15 KOLs across the 7MM. We contacted institutions such as the Yale University School of Medicine, Tokyo Institute of Psychiatry, University of Chieti-Pescara, etc., among others. By obtaining the opinions of these experts, we gained a better understanding of the current and emerging treatment patterns in the Cocaine Use Disorder market, which will assist our clients in analyzing the overall epidemiology and market scenario.

Qualitative Analysis

We perform Qualitative and Market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, designation, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in trials for Cocaine Use Disorder, one of the most important primary endpoints was achieving hemolysis control, LDH normalization, etc. Based on these, the overall efficacy is evaluated.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Because newly authorized drugs are often expensive, some patients escape receiving proper treatment or use off-label, less expensive prescriptions. Reimbursement plays a critical role in how innovative treatments can enter the market. The cost of the medicine, compared to the benefit it provides to patients who are being treated, sometimes determines whether or not it will be reimbursed. Regulatory status, target population size, the setting of treatment, unmet needs, the number of incremental benefit claims, and prices can all affect market access and reimbursement possibilities.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Cocaine Use Disorder (CUD) Report Insights

• Patient Population
• Therapeutic Approaches
• Cocaine Use Disorder Market Size and Trends
• Existing Market Opportunity

Cocaine Use Disorder (CUD) Report Key Strengths

• Eleven-year Forecast
• The 7MM Coverage
• Cocaine Use Disorder Epidemiology Segmentation
• Key Cross Competition

Cocaine Use Disorder (CUD) Report Assessment

• Current Treatment Practices
• Reimbursements
• Market Attractiveness
• Qualitative Analysis (SWOT, Conjoint Analysis, Unmet needs)

Key Questions:

• Would there be any changes observed in the current treatment approach?
• Will there be any improvements in Cocaine Use Disorder management recommendations?
• Would research and development advances pave the way for future tests and therapies for Cocaine Use Disorder?
• Would the diagnostic testing space experience a significant impact and lead to a positive shift in the treatment landscape of Cocaine Use Disorder?
• What kind of uptake will the new therapies witness in the coming years in Cocaine Use Disorder patients?

Table of Contents

1. Key Insights

2. Report Introduction

3. CUD Market Overview at a Glance

• 3.1. Market Share (%) Distribution of CUD in 2023 in the 7MM
• 3.2. Market Share (%) Distribution of CUD in 2034 in the 7MM

4. Methodology

5. Executive Summary of CUD

6. Key Events

7. Disease Background and Overview of CUD

• 7.1. Introduction to CUD
• 7.2. Signs and Symptoms
• 7.3. DSM 5 Criteria for Cocaine Use Disorder: Signs and Symptoms of CUD
• 7.4. Classification of CUD
• 7.5. Etiology
• 7.6. Risk Factors
• 7.7. Pathophysiology
  • 7.7.1. Dopamine Brain Rewarding Mechanism
  • 7.7.2. Disruption of Serotonin Levels at the Ventral Pallidum
  • 7.7.3. Cholinergic Pathway
• 7.8. Complications of Cocaine Use
• 7.9. Diagnosis
  • 7.9.1 . Key Diagnostic Factors
  • 7.9.2. Other Diagnostic Factors
  • 7.9.3. Diagnostic Tests
  • 7.9.4. DSM-5 Diagnostic Criteria for CUD
  • 7.9.5. DSM-5 Diagnostic Criteria for Diagnosing and Classifying Substance Use Disorders

8. Management and Treatment

• 8.1. Nonpharmacological Treatment
• 8.2. Pharmacological Treatment
• 8.3. Treatment Guidelines
  • 8.3.1. Substance Abuse and Mental Health Services Administration (SAMHSA) Recommendations
  • 8.3.2. American Addiction Center (AAC) Treatment Recommendation
  • 8.3.3. The German National Strategy on Drug and Addiction Policy
  • 8.3.4. International Society of Substance Use Professionals
  • 8.3.5. Drug Misuse and Dependence: UK Guidelines on Clinical Management
  • 8.3.6. Evidence on Pharmacotherapies for Cocaine Use Disorder, Stratified by Drug Class

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: The 7MM
  • 9.2.1 . Diagnosed Prevalent Cases of CUD
  • 9.2.2 . Gender-specific Cases of CUD
  • 9.2.3 . Age-specific Cases of CUD
  • 9.2.4. Severity-specific Cases of CUD
• 9.3. Total diagnosed prevalent cases of CUD in the 7MM
• 9.4. Total Treated cases of CUD in the 7MM
• 9.5. The United States
  • 9.5.1. Total diagnosed prevalent cases of CUD in the US
  • 9.5.2. Gender-specific cases of CUD in the US
  • 9.5.3. Age-specific cases of CUD in the US
  • 9.5.4. Severity-specific cases of CUD in the US
  • 9.5.5. Total Treated cases of CUD in the US
• 9.6. EU4 and the UK
  • 9.6.1. Total diagnosed prevalent cases of CUD in EU4 and the UK
  • 9.6.2. Gender-specific cases of CUD in EU4 and the UK
  • 9.6.3. Age-specific cases of CUD in EU4 and the UK
  • 9.6.4. Severity-specific cases of CUD in EU4 and the UK
  • 9.6.5. Total Treated cases of CUD in EU4 and the UK
• 9.7. Japan
  • 9.7.1. Total diagnosed prevalent cases of CUD in Japan
  • 9.7.2. Gender-specific cases of CUD in Japan
  • 9.7.3. Age-specific cases of CUD in Japan
  • 9.7.4. Severity-specific cases of CUD in Japan
  • 9.7.5. Total Treated cases of CUD in Japan

10. Patient Journey

11. Emerging Therapies

• 11.1. Key Cross Competition
• 11.2. Mavoglurant (STP7/AFQ056): STALICLA
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Developmental Activities
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst View

12. Market Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebates
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptake
• 12.5. Total Market Size of CUD in the 7MM
• 12.6. United States Market Size
  • 12.6.1. Total Market Size of CUD in the United States
  • 12.6.2. Market Size of CUD by Therapies in the United States
• 12.7. EU4 and the UK Market Size
  • 12.7.1. Total Market Size of CUD in EU4 and the UK
  • 12.7.2. Market Size of CUD by Therapies in EU4 and the UK
• 12.8. Japan Market Size
  • 12.8.1. Total Market Size of CUD in Japan
  • 12.8.2. Market Size of CUD by Therapies in Japan

13. KOL Views

14. SWOT Analysis

15. Unmet Needs

16. Appendix

• 16.1. Bibliography
• 16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer